Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT)
The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN)
Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT)
The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN)
Nipocalimab 延緩或預防了嚴重的胎兒貧血，在 2 期 UNITY 研究中，54% 的研究參與者在 32 周或之後無需宮內輸血 (IUT) 就實現了活產
AZALEA 3期臨床研究目前正在招收患者：Nipocalimab是臨床開發中唯一一種用於有嚴重胎兒和新生兒溶血性疾病（HDFN）風險的妊娠的療法
